Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy

被引:27
作者
Malyszko, J [1 ]
Malyszko, JS [1 ]
Hryszko, T [1 ]
Mysliwiec, M [1 ]
机构
[1] Med Univ, Dept Nephrol & Transplantol, PL-15540 Bialystok, Poland
关键词
TAFI; diabetic nephropathy; hemodialyses; peritoneal dialyses; endothelium;
D O I
10.1160/TH03-04-0243
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients dialyzed due to diabetic nephropathy are at a higher risk of death due to cardiovascular complications than dialyzed non-diabetic patients. Disturbances in hemostasis may play a role in the vascular complications of diabetes mellitus. It has been postulated that TAFI-thrombin activatable fibrinolysis inhibitor, which couples two opposite systems: coagulation and fibrinolysis, may be involved in the mechanism of vascular endothelial damage in diabetic patients. We assessed: TAR and TAFIa, markers of ongoing coagulation: thrombin-antithrombin complexes, prothrombin fragments 1+2, a marker of ongoing fibrinolysis: plasm in-anti plasmin complexes in diabetic and non-diabetic patients on hemodialyses-HD, peritoneal dialyses-CAPD, patietris with chronic renal failure with and without diabetic nephropathy on conservative treatment. Both groups of dialyzed diabetic patients have a higher concentration of markers of ongoing coagulation and TAR activity when compared to dialyzed non-diabetic patients. Linear regression analysis showed that TAR concentration was directly related to albumin in HD and CAPD patients without diabetic nephropathy, whereas TAFIa correlated with triglycericles, fibrinogen and leukocytes count in this group. When evaluated separately (HD, CAPD), significant correlations between TAFIa and triglycericles and fibrinogen were found only in diabetic CAPD patients. Multivariate analysis showed no correlation between TAR and other parameters studied. In conclusion, elevated circulating TAR and TAFIa might be a new link in the pathogenesis of impaired fibrinolysis in diabetic nephropathy, and thus atherosclerosis progression, particularly in CAPD patients. Hypercoagulable state observed in diabetic patients on conservative treatment and maintained on dialyses may contribute to the higher cardiovascular mortality in this population. In these patients there is also evidence of endothelial injury, and probably secondary activation of the coagulation cascade.
引用
收藏
页码:480 / 486
页数:7
相关论文
共 46 条
[1]  
ALMER LO, 1975, ACTA MED SCAND, V198, P101
[2]  
Alwakeel J., 1996, International Urology and Nephrology, V28, P255, DOI 10.1007/BF02550871
[3]  
Babazono T, 1996, ADV PERIT D, V12, P120
[4]   Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway [J].
Bajzar, L .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (12) :2511-2518
[5]   Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor [J].
Bajzar, L ;
Nesheim, M ;
Morser, J ;
Tracy, PB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (05) :2792-2798
[6]   Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms? [J].
Blann, AD .
BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 (07) :623-630
[7]  
CHRISTE M, 1984, THROMB HAEMOSTASIS, V52, P138
[8]   Activated human protein C prevents thrombin-induced thromboembolism in mice - Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation [J].
Gresele, P ;
Momi, S ;
Berrettini, M ;
Nenci, GG ;
Schwarz, HP ;
Semeraro, N ;
Colucci, M .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (03) :667-676
[9]   Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients [J].
Hori, Y ;
Gabazza, EC ;
Yano, Y ;
Katsuki, A ;
Suzuki, K ;
Adachi, Y ;
Sumida, Y .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (02) :660-665
[10]   A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients [J].
Hryszko, T ;
Malyszko, J ;
Malyszko, JS ;
Brzosko, S ;
Pawlak, K ;
Mysliwiec, M .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (08) :1692-1696